Consistent with previous findings in topotecan-treated and -resistant ovarian cancer cells [21], we found that HERC5 was upregulated in LM after LDM topotecan treatment and in HT29-topotecan resistant cell lines (Figure S7C). The gene discussed is HERC5; the disease is ovarian cancer.